TY - JOUR
T1 - Bioengineering strategies for restoring vision
AU - Cehajic-Kapetanovic, Jasmina
AU - Singh, Mandeep S.
AU - Zrenner, Eberhart
AU - MacLaren, Robert E.
N1 - Funding Information:
We thank J. Brett (BA Arts and Graphics) and T. Buckley (BM BCh) from Eye Research Group Oxford for their help with the images and figure design. We acknowledge funding from the University of Oxford NIHR Biomedical Research Centre. J.C.-K. was also funded by the Global Ophthalmology Fellowship Awards Programme, Bayer, Switzerland. E.Z. was supported by the DFG excellence center EXC 307 (CIN Tübingen). R.E.M. was funded by an MRC i4i Award for clinical trials of retinal implants.
Publisher Copyright:
© 2022, Springer Nature Limited.
PY - 2023/4
Y1 - 2023/4
N2 - Late-stage retinal degenerative disease involving photoreceptor loss can be treated by optogenetic therapy, cell transplantation and retinal prostheses. These approaches aim to restore light sensitivity to the retina as well as visual perception by integrating neuronal responses for transmission to the cortex. In age-related macular degeneration, some cell-based therapies also aim to restore photoreceptor-supporting tissue to prevent complete photoreceptor loss. In the earlier stages of degeneration, gene-replacement therapy could attenuate retinal-disease progression and reverse loss of function. And gene-editing strategies aim to correct the underlying genetic defects. In this Review, we highlight the most promising gene therapies, cell therapies and retinal prostheses for the treatment of retinal disease, discuss the benefits and drawbacks of each treatment strategy and the factors influencing whether functional tissue is reconstructed and repaired or replaced with an electronic device, and summarize upcoming technologies for enhancing the restoration of vision.
AB - Late-stage retinal degenerative disease involving photoreceptor loss can be treated by optogenetic therapy, cell transplantation and retinal prostheses. These approaches aim to restore light sensitivity to the retina as well as visual perception by integrating neuronal responses for transmission to the cortex. In age-related macular degeneration, some cell-based therapies also aim to restore photoreceptor-supporting tissue to prevent complete photoreceptor loss. In the earlier stages of degeneration, gene-replacement therapy could attenuate retinal-disease progression and reverse loss of function. And gene-editing strategies aim to correct the underlying genetic defects. In this Review, we highlight the most promising gene therapies, cell therapies and retinal prostheses for the treatment of retinal disease, discuss the benefits and drawbacks of each treatment strategy and the factors influencing whether functional tissue is reconstructed and repaired or replaced with an electronic device, and summarize upcoming technologies for enhancing the restoration of vision.
UR - http://www.scopus.com/inward/record.url?scp=85123943439&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123943439&partnerID=8YFLogxK
U2 - 10.1038/s41551-021-00836-4
DO - 10.1038/s41551-021-00836-4
M3 - Review article
C2 - 35102278
AN - SCOPUS:85123943439
SN - 2157-846X
VL - 7
SP - 387
EP - 404
JO - Nature biomedical engineering
JF - Nature biomedical engineering
IS - 4
ER -